146 related articles for article (PubMed ID: 15785057)
1. Early videocapillaroscopic changes of the psoriatic skin after anti-tumour necrosis factor alpha treatment.
De Angelis R; Gasparini S; Bugatti L; Filosa G
Dermatology; 2005; 210(3):241-3. PubMed ID: 15785057
[No Abstract] [Full Text] [Related]
2. Autoimmunity by anti-tumour necrosis factor-alpha agents: the role of traditional therapies.
Antoniou C; Moustou AE; Vergou T; Stratigos A; Kalambokas A; Katsambas AD
J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):356-7. PubMed ID: 19686257
[No Abstract] [Full Text] [Related]
3. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
Moreno-Ramírez D
Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
[No Abstract] [Full Text] [Related]
4. [Infliximab].
Herrera E; Habicheyn S
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of biologics with traditional agents in psoriasis.
Guenther LC
Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
[TBL] [Abstract][Full Text] [Related]
6. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
[TBL] [Abstract][Full Text] [Related]
7. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
[TBL] [Abstract][Full Text] [Related]
8. [Up-date on the use of infliximab in dermatology. Introduction].
Sánchez-Carazo J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
[No Abstract] [Full Text] [Related]
9. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
[TBL] [Abstract][Full Text] [Related]
10. Infliximab: efficacy in psoriasis.
Arsiwala S
Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S25-34. PubMed ID: 23974692
[TBL] [Abstract][Full Text] [Related]
11. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
Goedkoop AY; Kraan MC; Teunissen MB; Picavet DI; de Rie MA; Bos JD; Tak PP
Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
[TBL] [Abstract][Full Text] [Related]
12. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
13. [Our experience with infliximab in reclacitrant cases of psoriasis].
Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
Santos-Juanes J; Coto-Segura P; Mas-Vidal A; Galache Osuna C
Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
[No Abstract] [Full Text] [Related]
15. New development in the treatment of psoriasis--infliximab.
Pietrzak A; Chodorowska G; Jazienicka I; Junak-Bojarska A; Roliński J
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):322-7. PubMed ID: 15315008
[TBL] [Abstract][Full Text] [Related]
16. [Body-weight changes in psoriatic patients on systemic treatment].
Forien M; Mahé E; Sin C; Marchal A; Sigal ML
Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
[No Abstract] [Full Text] [Related]
17. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
Takahashi MD; Castro LG; Romiti R
Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
[No Abstract] [Full Text] [Related]
18. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts.
Sánchez-Moya AI; Daudén E
Br J Dermatol; 2011 Jan; 164(1):208-9. PubMed ID: 21054332
[No Abstract] [Full Text] [Related]
19. Treatment of psoriasis: focus on clinic-based management with infliximab.
de Eusebio E; Armario-Hita JC; de Miquel VA
Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S5-16. PubMed ID: 24777571
[TBL] [Abstract][Full Text] [Related]
20. Consecutive use of different biological therapies in the treatment of psoriasis.
Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
